2023 World Conference on Lung Cancer (Posters)-EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma

EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

Researchers from Yonsei University College of Medicine in Seoul, Korea conducted a study to investigate the contribution of compound EGFR mutations and other co-mutations to the efficacy of EGFR-tyrosine kinase inhibitor (TKI) treatment in EGFR mutant lung adenocarcinoma. They retrospectively analyzed the tumor tissue and treatment outcomes of 76 treatment-naïve patients with EGFR mutant lung adenocarcinoma at a tertiary referral hospital from February 2019 to February 2023.<br /><br />The study found that 18 out of the 76 cases (23.7%) had compound EGFR mutations, with 13 cases (72.2%) having a combination of the typical mutations (E19del or L858R mutation) and atypical mutations, while the remaining 5 cases (27.8%) had a combination of atypical mutations. Among the patients, 28 cases (36.8%) had the L858R mutation, out of which 22 cases were identified as compound mutations. Other types of EGFR mutations, such as E19del mutations, were also identified.<br /><br />The researchers also examined co-occurring driver mutations and found that TP53 mutations were present in 48 cases (63.2%), while HER2 and MET mutations were observed in 3 (3.9%) and 6 (7.9%) cases, respectively.<br /><br />It was observed that the presence of any co-mutation in EGFR mutant lung adenocarcinoma was associated with a shorter progression-free survival compared to cases with only EGFR mutation (15.4 vs 46.1 months, p<0.003).<br /><br />The study concludes that the detection of compound EGFR mutations is important for the management and treatment of patients with EGFR mutant lung adenocarcinoma, as these mutations were associated with poor clinical outcomes. The researchers recommend using Next-Generation Sequencing-based analysis for the detection of compound mutations in clinical practice.

Asset Subtitle

Se Hyun Kwak

Meta Tag

Speaker Se Hyun Kwak

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Yonsei University College of Medicine

Seoul

Korea

compound EGFR mutations

co-mutations

EGFR-tyrosine kinase inhibitor

lung adenocarcinoma

treatment outcomes

tumor tissue

retrospective analysis